In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10–40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...

This paper reports the first in vivo testing of a resonant-heating stent toward wireless hyperthermia treatment of in-stent restenosis. The stent, made of gold-coated medical-grade stainless steel, is ...